<?xml version='1.0' encoding='utf-8'?>
<DocAnalytics><Metadata><XML_Analytics_Processor><Version>XAP--0.2--Cermine-2018.01Model-2019.03Mapper-10000</Version></XML_Analytics_Processor></Metadata><DocAnalyticsSections><DocAnalyticsSection name="ML-SVMClassifier"><Mainterm name="human" weight="0.986620780651" /><Mainterm name="progression free survival" weight="0.907763184133" /><Mainterm name="overall survival" weight="0.85513100939" /><Mainterm name="female" weight="0.674959384645" /><Mainterm name="gene mutation" weight="0.577384805525" /><Mainterm name="cetuximab" weight="0.573160508813" /><Mainterm name="adult" weight="0.515248435519" /><Mainterm name="major clinical study" weight="0.514111916147" /><Mainterm name="aged" weight="0.38056957606" /><Mainterm name="genetic analysis" weight="0.366899801092" /><Mainterm name="oxaliplatin" weight="0.350377921835" /><Mainterm name="capecitabine" weight="0.332148373124" /><Mainterm name="middle aged" weight="0.294774011447" /><Mainterm name="cancer chemotherapy" weight="0.25912824887" /><Mainterm name="protein phosphorylation" weight="0.249166379" /><Mainterm name="programmed death 1 ligand 1" weight="0.22518162304" /><Mainterm name="male" weight="0.214157345323" /><Mainterm name="drug efficacy" weight="0.20095716502" /><Mainterm name="cancer immunotherapy" weight="0.197178980895" /><Mainterm name="clinical article" weight="0.195762549729" /><Mainterm name="next generation sequencing" weight="0.187781950471" /><Mainterm name="crizotinib" weight="0.15974262356" /><Mainterm name="olaparib" weight="0.153206237829" /><Mainterm name="clinical outcome" weight="0.153159703735" /><Mainterm name="docetaxel" weight="0.152447854807" /><Mainterm name="fluorouracil" weight="0.151134999386" /><Mainterm name="doxycycline" weight="0.149206130601" /><Mainterm name="treatment response" weight="0.145178938087" /><Mainterm name="droplet digital polymerase chain reaction" weight="0.144648446433" /><Mainterm name="chemoradiotherapy" weight="0.140085219444" /><Mainterm name="multicenter study" weight="0.129607590969" /><Mainterm name="cancer mortality" weight="0.125414636639" /><Mainterm name="cyclophosphamide" weight="0.124216356826" /><Mainterm name="enzalutamide" weight="0.123964351477" /><Mainterm name="controlled study" weight="0.118727212239" /><Mainterm name="trastuzumab" weight="0.113479961696" /><Mainterm name="algorithm" weight="0.108846357304" /><Mainterm name="abiraterone" weight="0.108727109696" /><Mainterm name="metastasis" weight="0.105713083057" /><Mainterm name="randomized controlled trial (topic)" weight="0.104551285086" /><Mainterm name="outcome assessment" weight="0.100695171187" /><Mainterm name="randomized controlled trial" weight="0.0983601240339" /><Mainterm name="microsatellite instability" weight="0.0844084714921" /><Mainterm name="phase 3 clinical trial (topic)" weight="0.0839440302384" /><Mainterm name="scientific literature" weight="0.0834493659657" /><Mainterm name="clinical practice" weight="0.0811997198146" /><Mainterm name="cost effectiveness analysis" weight="0.0800940241102" /><Mainterm name="scoring system" weight="0.0792409354702" /><Mainterm name="regorafenib" weight="0.0788563060041" /><Mainterm name="bevacizumab" weight="0.0767693587742" /><Mainterm name="priority journal" weight="0.0756741135285" /><Mainterm name="comparative genomic hybridization" weight="0.0736887253894" /><Mainterm name="classification algorithm" weight="0.0719472292384" /><Mainterm name="zoledronic acid" weight="0.0683954242016" /><Mainterm name="follow up" weight="0.0632350963202" /><Mainterm name="cell proliferation" weight="0.0627379377457" /><Mainterm name="retrospective study" weight="0.0623340604617" /><Mainterm name="phylogeny" weight="0.0615554553456" /><Mainterm name="molecularly targeted therapy" weight="0.0613973966984" /><Mainterm name="rituximab" weight="0.0607312193804" /><Mainterm name="protein p53" weight="0.0600348654976" /><Mainterm name="panitumumab" weight="0.0595375775855" /><Mainterm name="very elderly" weight="0.0588822414773" /><Mainterm name="disease exacerbation" weight="0.0569617259303" /><Mainterm name="protein analysis" weight="0.0567289827498" /><Mainterm name="visceral metastasis" weight="0.055808858657" /><Mainterm name="tumor growth" weight="0.0554646861486" /><Mainterm name="diarrhea" weight="0.0545613514276" /><Mainterm name="phase 1 clinical trial" weight="0.0545411192045" /><Mainterm name="sarcoma" weight="0.0541937352188" /><Mainterm name="drug tolerability" weight="0.0541015709236" /><Mainterm name="comparative study" weight="0.0534194437885" /><Mainterm name="lapatinib" weight="0.0529982586843" /><Mainterm name="metastatic breast cancer" weight="0.0519003286315" /><Mainterm name="pertuzumab" weight="0.0517137803937" /><Mainterm name="x-ray computed tomography" weight="0.0516422553239" /><Mainterm name="graft versus host reaction" weight="0.0513615894225" /><Mainterm name="cabazitaxel" weight="0.051314830169" /><Mainterm name="disease specific survival" weight="0.0512110499248" /><Mainterm name="Gleason score" weight="0.0501046895839" /><Mainterm name="cardiac rhythm management device" weight="0.0493653127678" /><Mainterm name="epidermal growth factor receptor 2" weight="0.0490734731877" /><Mainterm name="quality of life" weight="0.0485856968281" /><Mainterm name="observational study" weight="0.0482205128606" /><Mainterm name="neutropenia" weight="0.0480959610219" /><Mainterm name="human epidermal growth factor receptor 2 positive breast cancer" weight="0.0476651009167" /><Mainterm name="adolescent" weight="0.0474026135661" /><Mainterm name="stromal cell derived factor 1" weight="0.0451486810611" /><Mainterm name="lenalidomide" weight="0.0450224457684" /><Mainterm name="gemcitabine" weight="0.0435503675724" /><Mainterm name="stomach cancer" weight="0.0422253049857" /><Mainterm name="patient compliance" weight="0.0422087815404" /><Mainterm name="doxorubicin" weight="0.0419480038247" /><Mainterm name="ifosfamide" weight="0.0417199069671" /><Mainterm name="mortality" weight="0.0413787799939" /><Mainterm name="dysphagia" weight="0.0413560144829" /><Mainterm name="melanoma" weight="0.0413504608268" /><Mainterm name="monotherapy" weight="0.0412513768632" /><Mainterm name="young adult" weight="0.0400925221866" /><Mainterm name="cell growth" weight="0.0397718736489" /></DocAnalyticsSection><DocAnalyticsSection name="ML-LabelProximity"><Mainterm name="progression free survival" weight="0.5005642175674438" /><Mainterm name="oxaliplatin" weight="0.46347475051879883" /><Mainterm name="folinic acid" weight="0.46132248640060425" /><Mainterm name="carboplatin" weight="0.4405725598335266" /><Mainterm name="gemcitabine" weight="0.4173434376716614" /><Mainterm name="phase 2 clinical trial" weight="0.4113088548183441" /><Mainterm name="paclitaxel" weight="0.40907755494117737" /><Mainterm name="phase 3 clinical trial (topic)" weight="0.39508748054504395" /><Mainterm name="irinotecan" weight="0.39369866251945496" /><Mainterm name="nivolumab" weight="0.3892955780029297" /><Mainterm name="cetuximab" weight="0.37212643027305603" /><Mainterm name="metastatic melanoma" weight="0.3712819814682007" /><Mainterm name="pembrolizumab" weight="0.371163010597229" /><Mainterm name="fluorouracil" weight="0.36907821893692017" /><Mainterm name="erlotinib" weight="0.36789757013320923" /><Mainterm name="adjuvant chemotherapy" weight="0.3656909763813019" /><Mainterm name="overall survival" weight="0.3654686212539673" /><Mainterm name="docetaxel" weight="0.35651421546936035" /><Mainterm name="cancer immunotherapy" weight="0.35639095306396484" /><Mainterm name="bevacizumab" weight="0.35538747906684875" /><Mainterm name="ipilimumab" weight="0.35208702087402344" /><Mainterm name="cyclophosphamide" weight="0.34837931394577026" /><Mainterm name="cytarabine" weight="0.34316936135292053" /><Mainterm name="programmed death 1 receptor" weight="0.34235095977783203" /><Mainterm name="drug tolerability" weight="0.33644622564315796" /><Mainterm name="etoposide" weight="0.3309403657913208" /><Mainterm name="trastuzumab" weight="0.324692040681839" /><Mainterm name="phase 1 clinical trial (topic)" weight="0.323428750038147" /><Mainterm name="phase 2 clinical trial (topic)" weight="0.32185453176498413" /><Mainterm name="chemotherapy" weight="0.31206995248794556" /><Mainterm name="rituximab" weight="0.3118710517883301" /><Mainterm name="epidermal growth factor receptor 2" weight="0.3089333772659302" /><Mainterm name="treatment outcome" weight="0.3076738715171814" /><Mainterm name="sorafenib" weight="0.302151620388031" /><Mainterm name="treatment failure" weight="0.29647281765937805" /><Mainterm name="gastrointestinal endoscopy" weight="0.29580986499786377" /><Mainterm name="vincristine" weight="0.2954733669757843" /><Mainterm name="imatinib" weight="0.29524457454681396" /><Mainterm name="cytotoxic T lymphocyte antigen 4" weight="0.29467546939849854" /><Mainterm name="disease free survival" weight="0.29446738958358765" /><Mainterm name="life expectancy" weight="0.293006956577301" /><Mainterm name="health care planning" weight="0.286581814289093" /><Mainterm name="drug safety" weight="0.28455203771591187" /><Mainterm name="spectral domain optical coherence tomography" weight="0.28200387954711914" /><Mainterm name="programmed death 1 ligand 1" weight="0.28198733925819397" /><Mainterm name="nonhodgkin lymphoma" weight="0.2816501259803772" /><Mainterm name="drug cost" weight="0.28049612045288086" /><Mainterm name="transurethral resection" weight="0.2794281840324402" /><Mainterm name="randomized controlled trial (topic)" weight="0.27792179584503174" /><Mainterm name="erythema" weight="0.27788418531417847" /><Mainterm name="colonoscopy" weight="0.2754618525505066" /><Mainterm name="bacterial virulence" weight="0.27320414781570435" /><Mainterm name="non small cell lung cancer" weight="0.2721087634563446" /><Mainterm name="methotrexate" weight="0.2713078558444977" /><Mainterm name="clinical outcome" weight="0.27084213495254517" /><Mainterm name="public health service" weight="0.27048346400260925" /><Mainterm name="carcinoembryonic antigen" weight="0.2704637050628662" /><Mainterm name="clopidogrel" weight="0.2701171636581421" /><Mainterm name="ondansetron" weight="0.26924359798431396" /><Mainterm name="intestine obstruction" weight="0.26826196908950806" /><Mainterm name="maximum plasma concentration" weight="0.26774415373802185" /><Mainterm name="rivaroxaban" weight="0.2672015428543091" /><Mainterm name="neutropenia" weight="0.26668959856033325" /><Mainterm name="CD8+ T lymphocyte" weight="0.26648566126823425" /><Mainterm name="very elderly" weight="0.2659931480884552" /><Mainterm name="missense mutation" weight="0.26552918553352356" /><Mainterm name="kidney carcinoma" weight="0.2650531828403473" /><Mainterm name="highly active antiretroviral therapy" weight="0.26439252495765686" /><Mainterm name="heart death" weight="0.26371249556541443" /><Mainterm name="bioinformatics" weight="0.2623603940010071" /><Mainterm name="toxicity" weight="0.262154757976532" /><Mainterm name="multicenter study" weight="0.2617604732513428" /><Mainterm name="treatment response" weight="0.2616391181945801" /><Mainterm name="binding affinity" weight="0.26145070791244507" /><Mainterm name="next generation sequencing" weight="0.2613193392753601" /><Mainterm name="visual acuity" weight="0.2599250078201294" /><Mainterm name="cancer recurrence" weight="0.2592006027698517" /><Mainterm name="acute coronary syndrome" weight="0.25847482681274414" /><Mainterm name="lymph node dissection" weight="0.2573360502719879" /><Mainterm name="Hodgkin disease" weight="0.2571124732494354" /><Mainterm name="microbiome" weight="0.25697383284568787" /><Mainterm name="ST segment elevation myocardial infarction" weight="0.2561055123806" /><Mainterm name="amyotrophic lateral sclerosis" weight="0.25587522983551025" /><Mainterm name="doxorubicin" weight="0.2553413212299347" /><Mainterm name="heart infarction" weight="0.25530514121055603" /><Mainterm name="cisplatin" weight="0.2550294101238251" /><Mainterm name="health care policy" weight="0.2550012171268463" /><Mainterm name="health care survey" weight="0.254996657371521" /><Mainterm name="Clostridium difficile infection" weight="0.25499019026756287" /><Mainterm name="DNA repair" weight="0.2529250383377075" /><Mainterm name="hypokalemia" weight="0.25282371044158936" /><Mainterm name="transcriptome" weight="0.2521275281906128" /><Mainterm name="food and drug administration" weight="0.2520545423030853" /><Mainterm name="cardiovascular magnetic resonance" weight="0.2505675256252289" /><Mainterm name="tumor xenograft" weight="0.25029581785202026" /><Mainterm name="leukemia" weight="0.25027942657470703" /><Mainterm name="immune response" weight="0.24962177872657776" /><Mainterm name="Human immunodeficiency virus infection" weight="0.2490687221288681" /><Mainterm name="uterine cervix cancer" weight="0.24869319796562195" /><Mainterm name="vaccination" weight="0.2481871247291565" /></DocAnalyticsSection><DocAnalyticsSection name="Matching-Mainterm"><Mainterm matchCount="2" name="adenocarcinoma" section="Abstract" synonym="" /><Mainterm matchCount="1" name="adverse event" section="Abstract" synonym="adverse events" /><Mainterm matchCount="1" name="antineoplastic activity" section="Abstract" synonym="antitumor effect" /><Mainterm matchCount="1" name="association" section="Abstract" synonym="" /><Mainterm matchCount="1" name="biological marker" section="Abstract" synonym="biomarkers" /><Mainterm matchCount="5" name="chemotherapy" section="Abstract" synonym="" /><Mainterm matchCount="1" name="confidence interval" section="Abstract" synonym="" /><Mainterm matchCount="2" name="control" section="Abstract" synonym="" /><Mainterm matchCount="1" name="disease control" section="Abstract" synonym="" /><Mainterm matchCount="1" name="diseases" section="Abstract" synonym="disease" /><Mainterm matchCount="1" name="electric potential" section="Abstract" synonym="potential" /><Mainterm matchCount="1" name="folinic acid" section="Abstract" synonym="leucovorin" /><Mainterm matchCount="1" name="futurology" section="Abstract" synonym="future" /><Mainterm matchCount="1" name="growth" section="Abstract" synonym="" /><Mainterm matchCount="1" name="homologous recombination" section="Abstract" synonym="" /><Mainterm matchCount="1" name="hypertension" section="Abstract" synonym="" /><Mainterm matchCount="2" name="immunotherapy" section="Abstract" synonym="" /><Mainterm matchCount="1" name="leukopenia" section="Abstract" synonym="leucopenia" /><Mainterm matchCount="4" name="malignant neoplasm" section="Abstract" synonym="cancer" /><Mainterm matchCount="1" name="metastasis" section="Abstract" synonym="" /><Mainterm matchCount="1" name="neutropenia" section="Abstract" synonym="" /><Mainterm matchCount="1" name="nivolumab" section="Abstract" synonym="" /><Mainterm matchCount="1" name="oxaliplatin" section="Abstract" synonym="" /><Mainterm matchCount="1" name="patient" section="Abstract" synonym="patients" /><Mainterm matchCount="1" name="phase 2 clinical trial" section="Abstract" synonym="phase II study" /><Mainterm matchCount="1" name="phase 2 clinical trial" section="Abstract" synonym="phase II trial" /><Mainterm matchCount="1" name="platinum" section="Abstract" synonym="" /><Mainterm matchCount="1" name="progression free survival" section="Abstract" synonym="progression-free survival" /><Mainterm matchCount="1" name="receptor" section="Abstract" synonym="" /><Mainterm matchCount="6" name="regorafenib" section="Abstract" synonym="" /><Mainterm matchCount="1" name="relative" section="Abstract" synonym="" /><Mainterm matchCount="2" name="study" section="Abstract" synonym="" /><Mainterm matchCount="1" name="survival" section="Abstract" synonym="" /><Mainterm matchCount="1" name="systemic therapy" section="Abstract" synonym="" /><Mainterm matchCount="1" name="therapy" section="Abstract" synonym="" /><Mainterm matchCount="1" name="toxicity" section="Abstract" synonym="" /><Mainterm matchCount="1" name="tyrosine" section="Abstract" synonym="" /><Mainterm matchCount="3" name="adenocarcinoma" section="Para" synonym="" /><Mainterm matchCount="1" name="adjuvant" section="Para" synonym="" /><Mainterm matchCount="1" name="adjuvant therapy" section="Para" synonym="" /><Mainterm matchCount="1" name="adverse event" section="Para" synonym="adverse events" /><Mainterm matchCount="1" name="algorithm" section="Para" synonym="" /><Mainterm matchCount="7" name="analysis" section="Para" synonym="" /><Mainterm matchCount="1" name="aptitude" section="Para" synonym="ability" /><Mainterm matchCount="1" name="arm" section="Para" synonym="" /><Mainterm matchCount="1" name="Asia" section="Para" synonym="" /><Mainterm matchCount="2" name="assay" section="Para" synonym="" /><Mainterm matchCount="2" name="association" section="Para" synonym="" /><Mainterm matchCount="1" name="bleeding" section="Para" synonym="" /><Mainterm matchCount="1" name="bleeding tendency" section="Para" synonym="bleeding diathesis" /><Mainterm matchCount="1" name="blood clotting disorder" section="Para" synonym="coagulopathy" /><Mainterm matchCount="1" name="cell cycle" section="Para" synonym="" /><Mainterm matchCount="2" name="cell death" section="Para" synonym="" /><Mainterm matchCount="3" name="cells" section="Para" synonym="cell" /><Mainterm matchCount="1" name="cetuximab" section="Para" synonym="" /><Mainterm matchCount="1" name="chemoradiotherapy" section="Para" synonym="chemoradiation" /><Mainterm matchCount="14" name="chemotherapy" section="Para" synonym="" /><Mainterm matchCount="1" name="chromosomal instability" section="Para" synonym="" /><Mainterm matchCount="3" name="cisplatin" section="Para" synonym="" /><Mainterm matchCount="1" name="clinical trial" section="Para" synonym="" /><Mainterm matchCount="1" name="computer assisted tomography" section="Para" synonym="computed tomography" /><Mainterm matchCount="1" name="confidence interval" section="Para" synonym="" /><Mainterm matchCount="1" name="confidence interval" section="Para" synonym="confidence intervals" /><Mainterm matchCount="2" name="consensus" section="Para" synonym="" /><Mainterm matchCount="3" name="control" section="Para" synonym="" /><Mainterm matchCount="1" name="coordination" section="Para" synonym="" /><Mainterm matchCount="5" name="death" section="Para" synonym="" /><Mainterm matchCount="2" name="disability" section="Para" synonym="" /><Mainterm matchCount="1" name="disease burden" section="Para" synonym="burden of disease" /><Mainterm matchCount="8" name="diseases" section="Para" synonym="disease" /><Mainterm matchCount="1" name="DNA" section="Para" synonym="" /><Mainterm matchCount="1" name="documentation" section="Para" synonym="" /><Mainterm matchCount="3" name="dose" section="Para" synonym="" /><Mainterm matchCount="1" name="drug dose reduction" section="Para" synonym="dose reduction" /><Mainterm matchCount="1" name="drug therapy" section="Para" synonym="medication" /><Mainterm matchCount="1" name="editorial" section="Para" synonym="" /><Mainterm matchCount="1" name="electric potential" section="Para" synonym="potential" /><Mainterm matchCount="1" name="error" section="Para" synonym="" /><Mainterm matchCount="3" name="fluoropyrimidine" section="Para" synonym="" /><Mainterm matchCount="1" name="folinic acid" section="Para" synonym="leucovorin" /><Mainterm matchCount="1" name="follow up" section="Para" synonym="lost to follow-up" /><Mainterm matchCount="1" name="futurology" section="Para" synonym="future" /><Mainterm matchCount="1" name="gastroesophageal junction" section="Para" synonym="" /><Mainterm matchCount="2" name="gene" section="Para" synonym="" /><Mainterm matchCount="2" name="gene" section="Para" synonym="genes" /><Mainterm matchCount="1" name="genome" section="Para" synonym="" /><Mainterm matchCount="1" name="global disease burden" section="Para" synonym="global burden of disease" /><Mainterm matchCount="1" name="heart disease" section="Para" synonym="cardiac disease" /><Mainterm matchCount="1" name="hematemesis" section="Para" synonym="" /><Mainterm matchCount="1" name="history" section="Para" synonym="" /><Mainterm matchCount="1" name="homologous recombination" section="Para" synonym="" /><Mainterm matchCount="2" name="hypertension" section="Para" synonym="" /><Mainterm matchCount="1" name="imaging" section="Para" synonym="" /><Mainterm matchCount="3" name="immunotherapy" section="Para" synonym="" /><Mainterm matchCount="1" name="incidence" section="Para" synonym="" /><Mainterm matchCount="1" name="indel mutation" section="Para" synonym="insertions and deletions" /><Mainterm matchCount="1" name="information processing" section="Para" synonym="data collection" /><Mainterm matchCount="1" name="informed consent" section="Para" synonym="" /><Mainterm matchCount="1" name="infusion" section="Para" synonym="" /><Mainterm matchCount="1" name="institutional review" section="Para" synonym="" /><Mainterm matchCount="1" name="jurisprudence" section="Para" synonym="will" /><Mainterm matchCount="1" name="leukopenia" section="Para" synonym="leucopenia" /><Mainterm matchCount="2" name="life" section="Para" synonym="" /><Mainterm matchCount="8" name="malignant neoplasm" section="Para" synonym="cancer" /><Mainterm matchCount="1" name="marker" section="Para" synonym="" /><Mainterm matchCount="1" name="metastasis" section="Para" synonym="metastases" /><Mainterm matchCount="1" name="methodology" section="Para" synonym="" /><Mainterm matchCount="1" name="microsatellite instability" section="Para" synonym="" /><Mainterm matchCount="1" name="model" section="Para" synonym="" /><Mainterm matchCount="1" name="mortality" section="Para" synonym="" /><Mainterm matchCount="2" name="mustard gas" section="Para" synonym="lost" /><Mainterm matchCount="1" name="mutation" section="Para" synonym="" /><Mainterm matchCount="2" name="neoplasm" section="Para" synonym="tumor" /><Mainterm matchCount="1" name="neutropenia" section="Para" synonym="" /><Mainterm matchCount="3" name="nivolumab" section="Para" synonym="" /><Mainterm matchCount="1" name="nuclear magnetic resonance" section="Para" synonym="magnetic resonance" /><Mainterm matchCount="7" name="oxaliplatin" section="Para" synonym="" /><Mainterm matchCount="1" name="paclitaxel" section="Para" synonym="" /><Mainterm matchCount="6" name="patient" section="Para" synonym="" /><Mainterm matchCount="41" name="patient" section="Para" synonym="patients" /><Mainterm matchCount="1" name="patient history of chemotherapy" section="Para" synonym="prior chemotherapy" /><Mainterm matchCount="1" name="pembrolizumab" section="Para" synonym="" /><Mainterm matchCount="1" name="performance" section="Para" synonym="" /><Mainterm matchCount="2" name="phase 2 clinical trial" section="Para" synonym="phase II study" /><Mainterm matchCount="1" name="phase 3 clinical trial" section="Para" synonym="phase III trial" /><Mainterm matchCount="1" name="platinum" section="Para" synonym="" /><Mainterm matchCount="1" name="practice guideline" section="Para" synonym="guidelines" /><Mainterm matchCount="1" name="primary tumor" section="Para" synonym="primary tumors" /><Mainterm matchCount="2" name="progression free survival" section="Para" synonym="progression free" /><Mainterm matchCount="1" name="publication" section="Para" synonym="manuscript" /><Mainterm matchCount="3" name="ramucirumab" section="Para" synonym="" /><Mainterm matchCount="1" name="rank sum test" section="Para" synonym="Wilcoxon test" /><Mainterm matchCount="1" name="recurrent disease" section="Para" synonym="recurrence" /><Mainterm matchCount="1" name="reduction (chemistry)" section="Para" synonym="reduction" /><Mainterm matchCount="11" name="regorafenib" section="Para" synonym="" /><Mainterm matchCount="1" name="relative" section="Para" synonym="" /><Mainterm matchCount="1" name="review" section="Para" synonym="" /><Mainterm matchCount="1" name="risk" section="Para" synonym="" /><Mainterm matchCount="3" name="safety" section="Para" synonym="" /><Mainterm matchCount="1" name="sensor" section="Para" synonym="" /><Mainterm matchCount="2" name="standard" section="Para" synonym="" /><Mainterm matchCount="1" name="statistical significance" section="Para" synonym="" /><Mainterm matchCount="1" name="statistics" section="Para" synonym="" /><Mainterm matchCount="2" name="stomach cancer" section="Para" synonym="gastric cancer" /><Mainterm matchCount="11" name="study" section="Para" synonym="" /><Mainterm matchCount="1" name="survivor" section="Para" synonym="survivors" /><Mainterm matchCount="1" name="swallow (bird)" section="Para" synonym="swallow" /><Mainterm matchCount="1" name="tablet" section="Para" synonym="tablets" /><Mainterm matchCount="3" name="therapy" section="Para" synonym="" /><Mainterm matchCount="1" name="time" section="Para" synonym="" /><Mainterm matchCount="1" name="tissues" section="Para" synonym="tissue" /><Mainterm matchCount="1" name="tomography" section="Para" synonym="" /><Mainterm matchCount="1" name="toxicity" section="Para" synonym="" /><Mainterm matchCount="1" name="training" section="Para" synonym="" /><Mainterm matchCount="2" name="trastuzumab" section="Para" synonym="" /><Mainterm matchCount="1" name="univariate analysis" section="Para" synonym="" /><Mainterm matchCount="1" name="writing" section="Para" synonym="" /></DocAnalyticsSection><DocAnalyticsSection name="Matching-EMMANS"><EmmansTerm matchCount="2" name="MSK" synonym="MSK" /><EmmansTerm matchCount="1" name="SAS" synonym="SAS Institute" /><EmmansTerm matchCount="1" name="Muro" synonym="Muro" /><EmmansTerm matchCount="2" name="Kettering" synonym="Kettering" /><EmmansTerm matchCount="2" name="Sloan Kettering" synonym="Sloan Kettering" /></DocAnalyticsSection><DocAnalyticsSection name="F1" type="Summary"><Mainterm FValueGroup="A &gt;= 0.85" name="human" /><Mainterm FValueGroup="A &gt;= 0.85" name="pertuzumab" /><Mainterm FValueGroup="B 0.75_0.85" name="female" /><Mainterm FValueGroup="B 0.75_0.85" name="male" /><Mainterm FValueGroup="C 0.50_0.75" name="adult" /><Mainterm FValueGroup="C 0.50_0.75" name="computer assisted tomography" /><Mainterm FValueGroup="C 0.50_0.75" name="controlled study" /><Mainterm FValueGroup="C 0.50_0.75" name="cyclophosphamide" /><Mainterm FValueGroup="C 0.50_0.75" name="docetaxel" /><Mainterm FValueGroup="C 0.50_0.75" name="doxycycline" /><Mainterm FValueGroup="C 0.50_0.75" name="dysphagia" /><Mainterm FValueGroup="C 0.50_0.75" name="epidermal growth factor receptor 2" /><Mainterm FValueGroup="C 0.50_0.75" name="fluorouracil" /><Mainterm FValueGroup="C 0.50_0.75" name="hematemesis" /><Mainterm FValueGroup="C 0.50_0.75" name="lenalidomide" /><Mainterm FValueGroup="C 0.50_0.75" name="major clinical study" /><Mainterm FValueGroup="C 0.50_0.75" name="nivolumab" /><Mainterm FValueGroup="C 0.50_0.75" name="overall survival" /><Mainterm FValueGroup="C 0.50_0.75" name="oxaliplatin" /><Mainterm FValueGroup="C 0.50_0.75" name="panitumumab" /><Mainterm FValueGroup="C 0.50_0.75" name="pembrolizumab" /><Mainterm FValueGroup="C 0.50_0.75" name="ramucirumab" /><Mainterm FValueGroup="C 0.50_0.75" name="randomized controlled trial (topic)" /><Mainterm FValueGroup="D 0.4_0.5" name="Gleason score" /><Mainterm FValueGroup="D 0.4_0.5" name="bevacizumab" /><Mainterm FValueGroup="D 0.4_0.5" name="capecitabine" /><Mainterm FValueGroup="D 0.4_0.5" name="carboplatin" /><Mainterm FValueGroup="D 0.4_0.5" name="cell proliferation" /><Mainterm FValueGroup="D 0.4_0.5" name="cetuximab" /><Mainterm FValueGroup="D 0.4_0.5" name="cisplatin" /><Mainterm FValueGroup="D 0.4_0.5" name="comparative genomic hybridization" /><Mainterm FValueGroup="D 0.4_0.5" name="crizotinib" /><Mainterm FValueGroup="D 0.4_0.5" name="diarrhea" /><Mainterm FValueGroup="D 0.4_0.5" name="doxorubicin" /><Mainterm FValueGroup="D 0.4_0.5" name="gemcitabine" /><Mainterm FValueGroup="D 0.4_0.5" name="irinotecan" /><Mainterm FValueGroup="D 0.4_0.5" name="jurisprudence" /><Mainterm FValueGroup="D 0.4_0.5" name="olaparib" /><Mainterm FValueGroup="D 0.4_0.5" name="paclitaxel" /><Mainterm FValueGroup="D 0.4_0.5" name="phylogeny" /><Mainterm FValueGroup="D 0.4_0.5" name="progression free survival" /><Mainterm FValueGroup="D 0.4_0.5" name="quality of life" /><Mainterm FValueGroup="D 0.4_0.5" name="retrospective study" /><Mainterm FValueGroup="D 0.4_0.5" name="rituximab" /><Mainterm FValueGroup="D 0.4_0.5" name="trastuzumab" /><Mainterm FValueGroup="D 0.4_0.5" name="tumor growth" /></DocAnalyticsSection><DocAnalyticsSection formula="modelscore &gt; 0.3 or (modelscore &gt; 0.04 and mainbodymatchcnt &gt; 0) or ( term in top100 modelscores and matchcount in title, keywords and abstract &gt; 0)" name="TermWeighted" type="Summary"><Mainterm FValueGroup="A &gt;= 0.85" name="metastasis" /><Mainterm FValueGroup="A &gt;= 0.85" name="neutropenia" /><Mainterm FValueGroup="A &gt;= 0.85" name="oxaliplatin" /><Mainterm FValueGroup="A &gt;= 0.85" name="progression free survival" /><Mainterm FValueGroup="A &gt;= 0.85" name="algorithm" /><Mainterm FValueGroup="C 0.5-0.75" name="cetuximab" /><Mainterm FValueGroup="A &gt;= 0.85" name="chemoradiotherapy" /><Mainterm FValueGroup="A &gt;= 0.85" name="follow up" /><Mainterm FValueGroup="C 0.5-0.75" name="microsatellite instability" /><Mainterm FValueGroup="A &gt;= 0.85" name="mortality" /><Mainterm FValueGroup="A &gt;= 0.85" name="stomach cancer" /><Mainterm FValueGroup="A &gt;= 0.85" name="trastuzumab" /><Mainterm FValueGroup="A &gt;= 0.85" name="human" /><Mainterm FValueGroup="A &gt;= 0.85" name="overall survival" /><Mainterm FValueGroup="A &gt;= 0.85" name="female" /><Mainterm FValueGroup="A &gt;= 0.85" name="gene mutation" /><Mainterm FValueGroup="A &gt;= 0.85" name="adult" /><Mainterm FValueGroup="A &gt;= 0.85" name="major clinical study" /><Mainterm FValueGroup="A &gt;= 0.85" name="aged" /><Mainterm FValueGroup="A &gt;= 0.85" name="genetic analysis" /><Mainterm FValueGroup="C 0.5-0.75" name="capecitabine" /></DocAnalyticsSection><DocAnalyticsSection final="true" formula="modelscore &gt; 0.2 &amp;&amp; section_matching_term_filter" name="Cutoff+SectionTermMatching" type="Summary"><Mainterm matchcount="0" name="human" weight="0.9866207806512705" /><Mainterm matchcount="3" name="progression free survival" weight="0.9077631841330094" /><Mainterm matchcount="0" name="overall survival" weight="0.8551310093897165" /><Mainterm matchcount="0" name="female" weight="0.6749593846448388" /><Mainterm matchcount="0" name="gene mutation" weight="0.5773848055247427" /><Mainterm matchcount="1" name="cetuximab" weight="0.5731605088133529" /><Mainterm matchcount="0" name="adult" weight="0.5152484355190282" /><Mainterm matchcount="0" name="major clinical study" weight="0.5141119161466389" /><Mainterm matchcount="0" name="aged" weight="0.3805695760598907" /><Mainterm matchcount="0" name="genetic analysis" weight="0.3668998010916366" /><Mainterm matchcount="8" name="oxaliplatin" weight="0.3503779218345143" /><Mainterm matchcount="0" name="capecitabine" weight="0.3321483731244901" /><Mainterm matchcount="0" name="middle aged" weight="0.29477401144669485" /><Mainterm matchcount="0" name="cancer chemotherapy" weight="0.25912824887038793" /><Mainterm matchcount="0" name="protein phosphorylation" weight="0.2491663789998085" /><Mainterm matchcount="0" name="programmed death 1 ligand 1" weight="0.22518162303988087" /><Mainterm matchcount="0" name="male" weight="0.21415734532295722" /><Mainterm matchcount="0" name="drug efficacy" weight="0.2009571650202808" /><Mainterm matchcount="1" name="antineoplastic activity" weight="&lt;0.2" /><Mainterm matchcount="1" name="biological marker" weight="&lt;0.2" /><Mainterm matchcount="1" name="bleeding tendency" weight="&lt;0.2" /><Mainterm matchcount="1" name="chemoradiotherapy" weight="&lt;0.2" /><Mainterm matchcount="1" name="chromosomal instability" weight="&lt;0.2" /><Mainterm matchcount="3" name="cisplatin" weight="&lt;0.2" /><Mainterm matchcount="1" name="computer assisted tomography" weight="&lt;0.2" /><Mainterm matchcount="1" name="disease control" weight="&lt;0.2" /><Mainterm matchcount="3" name="fluoropyrimidine" weight="&lt;0.2" /><Mainterm matchcount="2" name="folinic acid" weight="&lt;0.2" /><Mainterm matchcount="1" name="follow up" weight="&lt;0.2" /><Mainterm matchcount="1" name="hematemesis" weight="&lt;0.2" /><Mainterm matchcount="1" name="homologous recombination" weight="&lt;0.2" /><Mainterm matchcount="3" name="hypertension" weight="&lt;0.2" /><Mainterm matchcount="2" name="immunotherapy" weight="&lt;0.2" /><Mainterm matchcount="1" name="leukopenia" weight="&lt;0.2" /><Mainterm matchcount="1" name="metastasis" weight="&lt;0.2" /><Mainterm matchcount="1" name="microsatellite instability" weight="&lt;0.2" /><Mainterm matchcount="1" name="neutropenia" weight="&lt;0.2" /><Mainterm matchcount="4" name="nivolumab" weight="&lt;0.2" /><Mainterm matchcount="1" name="paclitaxel" weight="&lt;0.2" /><Mainterm matchcount="1" name="pembrolizumab" weight="&lt;0.2" /><Mainterm matchcount="2" name="phase 2 clinical trial" weight="&lt;0.2" /><Mainterm matchcount="1" name="platinum" weight="&lt;0.2" /><Mainterm matchcount="3" name="ramucirumab" weight="&lt;0.2" /><Mainterm matchcount="17" name="regorafenib" weight="&lt;0.2" /><Mainterm matchcount="2" name="stomach cancer" weight="&lt;0.2" /><Mainterm matchcount="2" name="trastuzumab" weight="&lt;0.2" /></DocAnalyticsSection></DocAnalyticsSections></DocAnalytics>